Cargando…

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride

BACKGROUND: Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jendle, J., Hyötyläinen, T., Orešič, M., Nyström, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684205/ https://www.ncbi.nlm.nih.gov/pubmed/34920733 http://dx.doi.org/10.1186/s12933-021-01431-2

Ejemplares similares

Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallel‐group study
por: Nyström, Thomas, et al.
Publicado: (2019)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2017)

Corrigendum: Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
por: Nyström, Thomas, et al.
Publicado: (2018)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Scherbak, Nikolai N., et al.
Publicado: (2023)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Scherbak, Nikolai N., et al.
Publicado: (2023)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report
por: Nakamura, Ikuko, et al.
Publicado: (2014)

Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate
por: Kaddurah‐Daouk, Rima, et al.
Publicado: (2018)

Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
por: Bizino, Maurice B., et al.
Publicado: (2019)

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
por: Li, Chun-jun, et al.
Publicado: (2012)

Urinary Metabolomic Profiling in Zucker Diabetic Fatty Rats with Type 2 Diabetes Mellitus Treated with Glimepiride, Metformin, and Their Combination
por: Dong, Yu, et al.
Publicado: (2016)

Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss
por: Simeone, Paola, et al.
Publicado: (2022)

Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
por: Rizzo, Manfredi, et al.
Publicado: (2014)

Oxylipid Profile of Low‐Dose Aspirin Exposure: A Pharmacometabolomics Study
por: Ellero‐Simatos, Sandrine, et al.
Publicado: (2015)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
por: Bode, B W, et al.
Publicado: (2010)

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
por: Rotroff, Daniel M., et al.
Publicado: (2016)

Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
por: Lambadiari, Vaia, et al.
Publicado: (2018)

Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
por: Kumarathurai, Preman, et al.
Publicado: (2021)

Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
por: Li, Chun-Jun, et al.
Publicado: (2014)

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis
por: Chang, Kai-Cheng, et al.
Publicado: (2020)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects
por: Nam, H W, et al.
Publicado: (2015)

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
por: Garber, A, et al.
Publicado: (2011)

Pharmacometabolomics-aided Pharmacogenomics in Autoimmune Disease
por: Katsila, Theodora, et al.
Publicado: (2016)

Pharmacometabolomics in Early‐Phase Clinical Development
por: Burt, T, et al.
Publicado: (2016)

Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication
por: Jian, Jingai, et al.
Publicado: (2023)

A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
por: van Eyk, Huub J., et al.
Publicado: (2019)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
por: Xie, Jing, et al.
Publicado: (2019)

Pharmacometabolomics Reveals That Serotonin Is Implicated in Aspirin Response Variability
por: Ellero-Simatos, S, et al.
Publicado: (2014)

A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients
por: Park, Jeong-Eun, et al.
Publicado: (2018)

Pharmacometabolomic Approach to Investigate the Response to Metformin in Patients with Type 2 Diabetes: A Cross-Sectional Study
por: Naja, Khaled, et al.
Publicado: (2023)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes - a prospective observational cohort study
por: Dahlén, Elsa M, et al.
Publicado: (2013)

Gut microbiome differences between metformin‐ and liraglutide‐treated T2DM subjects
por: Wang, Zhang, et al.
Publicado: (2017)

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
por: Inoue, Kana, et al.
Publicado: (2011)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kgeeb3aepk9jrnlq7i8c3v7c2f